Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

• Tác giả: Tahamtan Ahmadi, Nizar J Bahlis, Supratik Basu, Meral Beksac, Marc Braunstein, Jodi Carey, Robin Carson, Katherine Chastain, Yael C Cohen, Thierry Facon, Sebastian Grosicki, Cyrille Hulin, Vania Hungria, Maria Krevvata, Wojciech Legiec, Weiping Liu, Lorena Lopez-Masi, Angelo Maiolino, Josep M Martí, Morio Matsumoto, Aurore Perrot, Ludek Pour, Melissa Rowe, Kenshi Suzuki, Hiroyuki Takamatsu, Mehmet Turgut, Saad Z Usmani, Christopher P Venner, Jessica Vermeulen, Jianping Wang, Sonja Zweegman
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Nature medicine , 2025
• Bộ sưu tập: NCBI
• ID: 63188

Tóm tắt

Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10